These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35044729)

  • 1. Shedding Light on Classic Psychedelics and Self-Harm.
    Grossman DH; Hendricks PS
    J Clin Psychiatry; 2022 Jan; 83(2):. PubMed ID: 35044729
    [No Abstract]   [Full Text] [Related]  

  • 2. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LYSERGIC ACID DIETHYLAMIDE (LSD-25). 34. COMPARISON WITH EFFECT OF PSILOCYBIN ON THE SIAMESE FIGHTING FISH.
    ABRAMSON HA; GETTNER HH; ROLO A; DEAN G
    J Psychol; 1963 Oct; 56():363-74. PubMed ID: 14051981
    [No Abstract]   [Full Text] [Related]  

  • 4. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFECT OF MESCALINE, LYSERGIC ACID DIETHYLAMIDE AND PSILOCYBIN ON COLOR PERCEPTION.
    HARTMAN AM; HOLLISTER LE
    Psychopharmacologia; 1963 Aug; 4():441-51. PubMed ID: 14048565
    [No Abstract]   [Full Text] [Related]  

  • 6. Hallucinogen Use and Misuse in Older Adults.
    Redden WM; Paracha SU; Sheheryar Q
    Clin Geriatr Med; 2022 Feb; 38(1):55-66. PubMed ID: 34794703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sociological investigations of human enhancement drugs: The case of microdosing psychedelics.
    Liokaftos D
    Int J Drug Policy; 2021 Sep; 95():103099. PubMed ID: 33518382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [THE EXPERIENCE OF ORAL REGRESSION DUE TO THE EFFECT OF HALLUCINOGENS (LSD-25 AND PSILOCYBIN)].
    FERNANDEZ-CERDENO A; LEUNER H
    Z Psychosom Med; 1965; 11():45-54. PubMed ID: 14301325
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
    Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
    Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT).
    Diab H; Malcolm B
    J Psychoactive Drugs; 2021; 53(2):140-145. PubMed ID: 33242285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [COMPARISON OF PSYCHOPHARMACA LSD-25, BOL-148 AND PSILOCYBIN IN CLINICAL PRACTICE].
    KANDIC B; DORDEVIC D
    Vojnosanit Pregl; 1963 May; 20():275-9. PubMed ID: 14067329
    [No Abstract]   [Full Text] [Related]  

  • 16. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mescaline, LSD, psilocybin, and personality change.
    UNGER SM
    Psychiatry; 1963 May; 26():111-25. PubMed ID: 13995386
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(3):. PubMed ID: 33988930
    [No Abstract]   [Full Text] [Related]  

  • 19. THERAPEUTIC APPLICATION OF THE CHANGE IN CONSCIOUSNESS PRODUCED BY PSYCHOLYTICA (LSD, PSILOCYBIN, ETC.). THE PSYCHEDELIC EXPERIENCE IN THE TREATEMENT OF NEUROSIS.
    Alnaes R
    Acta Psychiatr Scand; 1964; 39(S180):397-409. PubMed ID: 14345225
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular structures of hallucinogenic substances: lysergic acid diethylamide, psilocybin, and 2,4,5-trimethoxyamphetamine.
    Baker RW; Chothia C; Pauling P; Weber HP
    Mol Pharmacol; 1973 Jan; 9(1):23-32. PubMed ID: 4685449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.